Longevity Compounds in 2025–2026 Research: Rapamycin, Senolytics, NAD+, and Peptides

Research Disclaimer: All compounds referenced are sold exclusively for in-vitro and laboratory research use. Not approved for human therapeutic use except where licensed. This content does not constitute medical advice.

Longevity research has accelerated dramatically since 2015. The identification of genetic and pharmacological interventions that extend lifespan in model organisms, the establishment of biomarkers of biological aging (epigenetic clocks), and the first human trials of compounds like rapamycin and dasatinib/quercetin have made anti-aging pharmacology one of the most active areas of translational research.

This article provides a current-state summary of the most researched longevity interventions, their mechanisms, and where the evidence stands.

Table of Contents#

1. The Major Pharmacological Longevity Targets
2. Rapamycin (mTOR Inhibition)
3. Senolytics: Clearing Senescent Cells
4. NAD+ Precursors: NMN and NR
5. GH Axis: Secretagogues and the Somatopause Question
6. Metformin: AMPK Activation and Longevity
7. Peptide Longevity Compounds: Semax, Selank, Epithalon
8. Epigenetic Clocks as Longevity Biomarkers
9. Current Research Landscape: Where Things Stand
10. Key References

The Major Pharmacological Longevity Targets#

The current pharmacological approaches to aging target a small number of conserved aging mechanisms:

Rapamycin (mTOR Inhibition)#

Rapamycin (sirolimus) is a macrolide that inhibits mTORC1 (mechanistic target of rapamycin complex 1) — the master sensor of amino acids, energy status, and growth factors.

Lifespan data#

• Mice (Harrison et al. 2009): rapamycin started at equivalent of age 60 in humans → 9–14% median lifespan extension. The finding that a single drug started in already-old animals can extend lifespan was landmark.
• ITP (Interventions Testing Program): multiple replications confirmed rapamycin extends both male and female mouse lifespan; some protocols achieve 20–30% extension
• Intermittent rapamycin: achieves lifespan extension with fewer side effects than continuous dosing
• Invertebrates: mTOR inhibition extends lifespan in C. elegans, Drosophila, and yeast

Mechanism of lifespan extension#

mTORC1 inhibition → autophagy upregulation → better clearance of damaged proteins and organelles → reduced senescent cell accumulation → healthier proteostasis → extended healthspan and lifespan.

Secondary mechanisms: reduced mRNA translation → less translational errors → better protein quality; reduced S6K1 activity → reduced insulin signaling → metabolic benefits.

Caveats#

Chronic rapamycin causes immunosuppression (mTOR required for immune responses), impaired wound healing, and testicular atrophy in males. Research protocols use intermittent dosing (every-other-week or once-weekly) to mitigate effects.

Senolytics: Clearing Senescent Cells#

Cellular senescence (irreversible cell cycle arrest, often triggered by DNA damage, oncogenic stress, or telomere shortening) accumulates with age. Senescent cells secrete the SASP (senescence-associated secretory phenotype) — pro-inflammatory cytokines, proteases, and growth factors that damage neighboring tissue.

Dasatinib + Quercetin (D+Q)#

The most studied senolytic combination:

• Dasatinib (a tyrosine kinase inhibitor): inhibits BCR-ABL, Src, and other kinases that senescent cells rely on for survival → senescent cell apoptosis
• Quercetin (a flavonoid): inhibits PI3K and Bcl-2 family proteins in senescent cells → apoptosis

Published data:

• Baker et al. (2011): clearing p16-positive senescent cells with genetic inducible system → extends healthspan and lifespan in mice
• Kirkland et al. (2017): D+Q clears senescent cells in aged mice → improves physical function
• Deschênes-Simard et al. (2022): D+Q improves pulmonary fibrosis, frailty indices
• Human pilot trials: small trials in IPF (idiopathic pulmonary fibrosis) and CKD (chronic kidney disease) showed reduced senescent cell markers

Navitoclax (ABT-263)#

A Bcl-2/Bcl-xL inhibitor. Clears senescent cells but causes thrombocytopenia (platelets also express Bcl-xL) — limiting human use. Used in mouse research with careful monitoring.

Fisetin#

A flavonoid with senolytic and senomorphic (SASP-suppressing) properties. Well-tolerated, orally bioavailable, crosses the BBB. Less potent than D+Q but notable for minimal toxicity.

NAD+ Precursors: NMN and NR#

Covered in detail in our NAD+ longevity article. Key summary:

• NAD+ declines 30–50% with age across tissues
• NMN and NR restore tissue NAD+ toward younger levels
• Key mechanisms: SIRT1 → PGC-1α → mitochondrial biogenesis; SIRT3 → SOD2 → ROS defense; SIRT6 → DNA repair
• Human data: NR and NMN elevate blood/muscle NAD+ in clinical trials; functional endpoints still being established in Phase 2/3 trials
• No serious adverse effects at tested doses

The NMN/NR field is still accumulating functional endpoint data (rather than just biomarker data). The first rigorous human trials showing functional longevity benefits are expected in 2025–2028.

GH Axis: Secretagogues and the Somatopause Question#

As covered in our HGH anti-aging article, the GH/IGF-1 axis presents a paradox:

• Lower IGF-1 → longer life in model organisms (Ames dwarf mice, C. elegans daf-2 mutants)
• Age-appropriate GH restoration → improves body composition, muscle function, bone density in aged humans and animals

The current research consensus: supraphysiological IGF-1 elevation is potentially pro-aging (supports mTOR, potentially oncogenic); maintaining IGF-1 at the lower end of the young-adult range (not declining to GHD levels) may be optimal.

This makes GH secretagogues (Ipamorelin + CJC-1295) potentially more appropriate for aging research than rhGH — they produce smaller, feedback-regulated IGF-1 elevation that is less likely to overshoot into the mTOR-activating range.

The IGF-1 window hypothesis: there is a U-shaped relationship between IGF-1 and healthspan — very low IGF-1 (GHD range) causes frailty; very high IGF-1 (acromegaly range) causes cancer risk; the goal is to maintain the middle range.

Metformin: AMPK Activation and Longevity#

Metformin, the first-line type 2 diabetes drug, has emerged as one of the most studied longevity compounds:

Mechanism#

• AMPK activation: metformin inhibits Complex I of the ETC (partially) → AMP/ATP ratio rises → AMPK activation
• AMPK → mTORC1 inhibition (via TSC1/2 phosphorylation) → autophagy
• AMPK → PGC-1α activation → mitochondrial biogenesis
• AMPK → FOXO activation → stress resistance genes

Longevity data#

• ITP mouse study: metformin slightly extends lifespan at low dose (4–6%); attenuates the benefits of rapamycin if combined at higher doses
• Human observational data: T2D patients on metformin have lower age-related disease incidence than non-diabetics NOT on metformin (suggesting a longevity effect)
• TAME trial (Targeting Aging with Metformin): ongoing first-of-its-kind FDA-approved trial testing metformin for slowing aging in humans; results expected ~2026–2027

Metformin + NMN interaction#

Important for research: metformin partially inhibits Complex I → reduces NAD+ cycling efficiency → may blunt the efficacy of NMN/NR supplementation. Studies combining metformin with NAD+ precursors should monitor this interaction.

Peptide Longevity Compounds: Semax, Selank, Epithalon#

Semax#

Neuroprotective ACTH analog. BDNF/NGF upregulation, anti-ischemic, cognitive enhancement. Covered in detail in our Semax article.

Aging relevance: age-related decline in BDNF contributes to cognitive deterioration. Semax is one of the few compounds with published data on BDNF restoration in aged rodent brain.

Selank#

Tuftsin-based anxiolytic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro). Russian-developed, registered in Russia.

• GABA-A modulation (anxiolytic)
• Upregulates BDNF and enkephalins
• Anti-inflammatory (reduces LPS-induced TNF-α, IL-1β)
• Anxiolytic without sedation (different from benzodiazepines)

Epithalon (Epitalon)#

Tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal gland peptide epithalamin:

• Telomerase activation: Epithalon activates hTERT expression in human cell lines and aged animals → telomere lengthening
• Melatonin-like pineal effects: antioxidant, circadian rhythm regulation
• Lifespan in rodents: several Russian studies report 10–25% lifespan extension in mice and rats
• Published limitations: most data is from Russian groups (Khavinson group, St. Petersburg Institute); independent replications are limited

Epithalon's published telomerase-activating activity in human diploid fibroblasts is one of the few peptide-based longevity interventions with direct telomere biology data.

Epigenetic Clocks as Longevity Biomarkers#

Epigenetic clocks (Horvath clock, GrimAge, DunedinPACE) measure DNA methylation patterns at hundreds of CpG sites to estimate biological age — often more accurately than chronological age for predicting mortality and age-related disease risk.

For research validation, epigenetic clocks are becoming standard endpoints in longevity intervention studies because:

• They capture multi-system biological aging in a single measurement
• They respond to anti-aging interventions (caloric restriction, rapamycin, NMN/NR all show epigenetic clock reversal in some studies)
• They are measurable in blood (accessible, non-invasive in humans)

Combining an epigenetic clock endpoint with functional endpoints (body composition, physical function, cognitive testing) gives a more complete picture of whether an anti-aging intervention is truly altering the aging trajectory.

Current Research Landscape: Where Things Stand#

The most validated interventions in 2025–2026 are caloric restriction, rapamycin (in rodents), and senolytics (moving into humans). NAD+ precursors have strong mechanistic rationale and growing human biomarker data but await functional endpoint trials. Peptide approaches remain primarily in the preclinical stage.

Key References#

1. López-Otín C, et al. (2023). "Hallmarks of aging: An expanding universe." Cell, 186(2):243–278.

2. Harrison DE, et al. (2009). "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." Nature, 460(7253):392–395.

3. Baker DJ, et al. (2011). "Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders." Nature, 479(7372):232–236.

4. Blagosklonny MV. (2019). "Rapamycin for longevity: opinion article." Aging (Albany NY), 11(19):8048–8067.

5. Gomes AP, et al. (2013). "Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell, 155(7):1624–1638.

6. Khavinson VKh, et al. (2003). "Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells." Bulletin of Experimental Biology and Medicine, 135(6):590–592.

Research Use Only: All compounds referenced are sold exclusively for in-vitro research and laboratory use. Not for human consumption. JuicedPharma does not provide medical advice.

Published by JuicedPharma Research Team · September 2026 · Category: Research Protocols & Science